

- chemotherapy in relation to hormone receptor status and other factors. *J Clin Oncol* 24: 1037–1044
- Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA (2007) HER2 and response to paclitaxel in node-positive breast cancer. *N Engl J Med* 357: 1496–1506
- Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE (1999) Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. *J Clin Oncol* 17: 460–469
- Kuerer HM, Singletary SE, Buzdar AU, Ames FC, Valero V, Buchholz TA, Ross MI, Puztai L, Hortobagyi GN, Hunt KK (2001) Surgical conservation planning after neoadjuvant chemotherapy for stage II and operable stage III breast carcinoma. *Am J Surg* 182: 601–608
- Mauri D, Pavlidis N, Ioannidis JP (2005) Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. *J Natl Cancer Inst* 97: 188–194
- Mauriac L, MacGrogan G, Avril A, Durand M, Floquet A, Debled M, Dilhuydy JM, Bonichon F (1999) Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonie Bordeaux Groupe Sein (IBBGS). *Ann Oncol* 10: 47–52
- Mazouni C, Peintinger F, Wan-Kau S, Andre F, Gonzalez-Angulo AM, Symmans WF, Meric-Bernstam F, Valero V, Hortobagyi GN, Puztai L (2007) Residual ductal carcinoma *in situ* in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. *J Clin Oncol* 25: 2650–2655
- Morrell LE, Lee YJ, Hurley J, Arias M, Mies C, Richman SP, Fernandez H, Donofrio KA, Raub Jr WA, Cassileth PA (1998) A phase II trial of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin in the treatment of patients with locally advanced breast carcinoma. *Cancer* 82: 503–511
- Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM (2006) The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. *Cancer* 107: 1248–1254
- Ring AE, Smith IE, Ashley S, Fulford LG, Lakhani SR (2004) Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer. *Br J Cancer* 91: 2012–2017
- Rouzier R, Extra JM, Carton M, Falcou MC, Vincent-Salomon A, Fourquet A, Pouillart P, Bourstyn E (2001) Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. *J Clin Oncol* 19: 3828–3835
- Rowan K (2009) Trastuzumab before breast surgery? Large trial says yes but does not quell debate. *J Natl Cancer Inst* 101: 448–449
- Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z (1995) Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. *J Am Coll Surg* 180: 297–306
- Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, Ah-See AK, Eremin O, Walker LG, Sarkar TK, Eggleton SP, Ogston KN (2002) Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. *J Clin Oncol* 20: 1456–1466
- van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L (2001) Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. *J Clin Oncol* 19: 4224–4237
- Wapnir IL, Anderson SJ, Mamounas EP, Geyer Jr CE, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. *J Clin Oncol* 24: 2028–2037
- Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B (2001) Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. *J Natl Cancer Inst Monogr* 30: 96–102



ELSEVIER

Original contribution

Metaplastic carcinoma of the breast[☆]

Nao Okada MD^{a,b,*}, Takahiro Hasebe MD, PhD^{a,*}, Motoki Iwasaki MD, PhD^c,
Nobuko Tamura MD^b, Sadako Akashi-Tanaka MD, PhD^b, Takashi Hojo MD^b,
Tatsuhiko Shibata MD, PhD^d, Yuko Sasajima MD, PhD^e,
Yae Kanai MD, PhD^f, Takayuki Kinoshita MD, PhD^b

^aPathology Consultation Service, Clinical Trials and Practice Support Division,
Center for Cancer Control and Information Services, National Cancer Center, Tokyo 104-0045, Japan

^bDepartment of Breast Surgery, National Cancer Center Hospital, Tokyo 104-0045, Japan

^cEpidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center,
Tokyo 104-0045, Japan

^dCancer Genomics Project, National Cancer Center Research Institute, Tokyo 104-0045, Japan

^eClinical Laboratory Division, National Cancer Center Hospital, Tokyo 104-0045, Japan

^fPathology Division, National Cancer Center Research Institute, Tokyo 104-0045, Japan

Received 4 October 2009; revised 23 November 2009; accepted 25 November 2009

Keywords:

Metaplastic carcinoma;
Invasive ductal carcinoma;
Invasive lobular
carcinoma;
Breast;
Prognosis

Summary The purposes of this study were to investigate whether the biological characteristics or outcomes of patients with metaplastic carcinoma, invasive ductal carcinoma, or invasive lobular carcinoma of the breast differ; to determine whether the metaplastic carcinoma subtypes have similar malignant potentials; and to identify accurate predictors of outcome in patients with metaplastic carcinoma. The subject comprised 6137 invasive ductal carcinoma patients, 301 invasive lobular carcinoma patients, and 46 metaplastic carcinoma patients of the breast. The metaplastic carcinomas were classified according to the World Health Organization classification. Multivariate analyses clearly demonstrated that the metaplastic carcinoma patients had a significantly poorer outcome than the invasive ductal carcinoma patients or the invasive lobular carcinoma patients independent of the nodal status or age not exceeding 39 years, whereas patients with triple-negative metaplastic carcinomas or triple-negative invasive lobular carcinomas had a poorer outcome than those with triple-negative invasive ductal carcinomas. Although no significant differences in clinical outcome were observed among the metaplastic carcinoma subtypes in multivariate analyses, an age not exceeding 39 years, the presence of skin invasion, and the presence of a squamous cell carcinoma component in nodal tumors were significant outcome predictors for metaplastic carcinoma patients. In conclusion, the results of this study clearly demonstrated that metaplastic carcinoma is more aggressive than invasive ductal carcinoma or invasive lobular carcinoma. Although the metaplastic carcinoma subtypes had no prognostic significance, an age not exceeding 39 years, the presence of skin invasion, and the presence

[☆] This study was supported in part by a Grant-in-Aid for Scientific Research (KAKENHI) (C) (19590378, 21590393) from the Japan Society for the Promotion of Science and a Grant-in-Aid for Cancer Research from the Ministry of Health, Labour, and Welfare of Japan (20-16, H21-006).

* Corresponding authors. Nao Okada is to be contacted at Department of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan. Takahiro Hasebe, Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, Tokyo 104-0045, Japan.

E-mail addresses: naookada@ncc.go.jp (N. Okada), thasebe@ncc.go.jp (T. Hasebe).

of a squamous cell carcinoma component in nodal tumors were significant predictors of outcome among metaplastic carcinoma patients.

© 2010 Elsevier Inc. All rights reserved.

1. Introduction

The World Health Organization (WHO) classifies metaplastic carcinoma (MPC) into (1) epithelial type and (2) mixed type [1]. Epithelial-type MPC is in turn classified into (1) squamous cell carcinoma, (2) adenocarcinoma with spindle cell differentiation, and (3) adenosquamous carcinoma, whereas mixed type of MPC is classified into (1) carcinoma with chondroid metaplasia, (2) carcinoma with osseous metaplasia, and (3) carcinosarcoma [1]. Several studies have investigated whether the biological characteristics of these MPC subtypes differ [2-19] and whether outcome predictors exist for patients with these MPC subtypes [2-7,9,10,13-15,18]. However, almost all these studies involved survival analyses performed for a small number of MPC cases or that only used univariate analyses [2-7,9,10,13-15,18]. Thus, whether the presently used subtype classification reflects the malignant potential of these lesions remains uncertain; and which factors are the most important predictors of outcome in patients with MPC remains controversial.

Furthermore, although patients with MPC are thought to exhibit a poorer outcome than patients with invasive ductal carcinoma (IDC) or invasive breast carcinoma [15,18], the survival periods of patients with MPC, IDC, or invasive lobular carcinoma (ILC) have not been compared using consecutive cases treated during the same period. Thus, no direct evidence indicating that MPC is more aggressive than IDC or ILC presently exists.

The purposes of this study were (1) to investigate whether the biological characteristics or outcomes of patients with MPC, IDC, or ILC of the breast differ; (2) to determine whether the MPC subtypes have similar malignant potentials; and (3) to identify accurate predictors of outcome in patients with MPC. The results of this study clearly demonstrated that patients with MPC have a significantly poorer outcome than patients with IDC or ILC; that the MPC subtype has no prognostic significance; and that an age not exceeding 39 years, the presence of skin invasion, and the presence of a squamous cell carcinoma component in nodal tumors were significant predictors of outcome among patients with MPC.

2. Materials and methods

2.1. Cases

The subject comprised 6137 consecutive cases of IDC, 301 consecutive cases of ILC, and 46 consecutive cases of MPC of the breast; all the subjects had undergone surgery at the

National Cancer Center Hospital between January 1982 and March 2007. For the MPC cases, all the breast carcinomas diagnosed as squamous cell carcinoma, epidermoid carcinoma, MPC, carcinosarcoma, carcinoma with spindle cell metaplasia, carcinoma with chondroid metaplasia, or carcinoma with osteoid metaplasia at the National Cancer Center Hospital between January 1982 and March 2007 were reviewed; 46 cases of MPC were subsequently identified.

Clinical information was obtained from the patients' medical records. All the patients were Japanese women, ranging in age from 20 to 98 years (median, 53 years). Overall, 2094 patients were premenopausal and 3056 were postmenopausal. A partial mastectomy had been performed in 1208 patients, a modified radical mastectomy had been performed in 3340, and a standard radical mastectomy had been performed in 1139. A level I and II axillary lymph node dissection had been performed in all the patients, and some of the patients had been received a level III axillary lymph node dissection.

The protocol (20-112) for this study was approved by the Institutional Review Board of the National Cancer Center.

2.2. Neoadjuvant therapy and adjuvant therapy

Because standardized neoadjuvant therapy and adjuvant therapy for patients with breast cancer were started in the 1990s at the National Cancer Center Hospital, the effect of neoadjuvant therapy or adjuvant therapy was examined in patients with IDCs, ILCs, or MPCs that had been surgically treated since January 1990. Neoadjuvant therapy was performed in 467 out of 2039 patients with IDC, 28 out of 111 patients with ILC, and 4 out of 46 patients with MPC, whereas adjuvant therapy was performed in 1756 out of 2303 patients with IDC, 101 out of 122 patients with ILC, and 18 out of 46 patients with MPC. Among these patients, 378 received chemotherapy, 749 received endocrine therapy, and 693 received combined chemoendocrine therapy. In the 1980s, the main chemotherapy regimens in use were anthracycline based; but nonanthracycline-based regimens were used in some patient populations. In the 1990s, the chemotherapy regimens in use were anthracycline based and were combined with or without taxane. In the 1980s, the endocrine therapy regimens in use were tamoxifen combined with or without a gonadotropin-releasing hormone agonist, whereas an aromatase inhibitor was additionally used in the 1990s.

2.3. Histologic examination of IDCs and ILCs

The following IDC and ILC characteristics were obtained from the pathologic diagnostic records, which




Fig. 1 Histologic features of MPC. A, Squamous cell carcinoma. The carcinoma cells invade as irregularly shaped solid nests showing squamous features with hyalinization. B, Adenosquamous carcinoma. The carcinoma cells invade as irregularly shaped solid nests and show squamous and tubular features. C, Carcinoma with chondroid metaplasia. The carcinoma cells invade as strands or solid nests with chondroid stroma. D, Squamous cell carcinoma in lymph node. Carcinoma cells metastasizing to the lymph node show squamous differentiation. E-G, Carcinosarcoma. Carcinosarcoma consists mainly of spindled tumor cells and epithelioid tumor cells admixed with pleomorphic tumor cells (E). Carcinosarcoma shows positive staining both for keratin (AE1/3) (F) and vimentin (G).

Table 1 Univariate analyses for identifying factors that are significantly different among patients with IDC, ILC, or MPC

No. of patients (%)			
Factors	IDC	ILC	<i>P</i> values; a, b, c MPC
Age, y			a, .002; b, .605; c, .033
≤39	655 (11)	15 (5)	6 (13)
>39	5481 (89)	286 (95)	40 (87)
Total	6136	301	46
Neoadjuvant therapy			a, .572; b, .023; c, .019
No	1572 (77)	83 (75)	42 (91)
Yes	467 (23)	28 (25)	4 (9)
Total	2039	111	46
Adjuvant therapy			a, .097; b, <.001; c, <.001
No	547 (24)	21 (17)	28 (61)
Yes	1756 (76)	101 (83)	18 (39)
Total	2303	122	46
ER			a, .085; b, <.001; c, <.001
Negative	615 (28)	25 (21)	21 (100)
Positive	1577 (72)	95 (79)	0
Total	2192	120	21
PR			a, .725; b, <.001; c, <.001
Negative	715 (33)	41 (34)	21 (100)
Positive	1477 (67)	79 (66)	0
Total	2192	120	21
HER2 category (0, 1 vs 2, 3)			a, .017; b, .052; c, .313
0 or 1	1799 (81)	107 (90)	25 (96)
2	189 (9)	6 (5)	0
3	226 (10)	6 (5)	1 (4)
Total	2214	119	26
Invasive tumor size (mm)			a, <.001; b, .090; c, .804
≤20	2214 (41)	83 (30)	13 (28)
>20	3242 (59)	193 (70)	33 (72)
Total	5456	276	46
Skin invasion			a, .069; b, .037; c, .292
Absent	5002 (92)	247 (89)	37 (84)
Present	407 (8)	29 (11)	7 (16)
Total	5409	276	44
Lymph vessel invasion			a, <.001; b, <.001; c, .001

Table 1 (continued)

No. of patients (%)			
Factors	IDC	ILC	<i>P</i> values; a, b, c MPC
Absent	2848 (47)	178 (60)	41 (89)
Present	3160 (53)	118 (40)	5 (11)
Total	6008	296	46
Blood vessel invasion			a, .051; b, .230; c, .597
Absent	5589 (93)	285 (96)	45 (98)
Present	393 (7)	11 (4)	1 (2)
Total	5983	296	46
Lymph node metastasis			a, .963; b, .461; c, .499
Absent	3716 (60)	183 (61)	29 (66)
Present	2430 (40)	119 (39)	15 (34)
Total	6147	302	44

NOTE. *P* value a, IDC vs ILC; *P* value b, IDC vs MPC; *P* value c, ILC vs MPC.

were completed by 2 or 3 pathologists per case at the time of treatment: (1) skin invasion (absent, present), (2) lymph vessel invasion (absent, present), (3) blood vessel invasion (absent, present), and (4) lymph node metastasis (absent, present).

2.4. Histologic examination of MPCs

Serial sections of each MPC tumor were cut from paraffin blocks. One section from each tumor was stained with hematoxylin and eosin and examined histologically to confirm the diagnosis, and another section was subjected to immunohistochemistry. The following 14 histologic features of primary invasive MPCs were evaluated, and several of these histologic features (numbers 7 to 14) were evaluated according to the WHO classification [1]: (1) invasive tumor size (≤20, >20 to ≤50, >50 mm), (2) skin invasion (absent, present), (3) histologic grade (1, 2, 3; only for carcinoma component) [20], (4) number of mitotic figures in 10 high-power-fields, (5) lymph vessel invasion (absent, present), (6) blood vessel invasion (absent, present), (7) tumor necrosis (absent/≤30%, >30%), (8) MPC type (epithelial, mixed), (9) squamous cell carcinoma versus other types of carcinoma (Fig. 1A), (10) adenocarcinoma with spindle cell differentiation versus other types of carcinoma, (11) adenosquamous carcinoma versus other types of carcinoma (Fig. 1B), (12) carcinoma with chondroid metaplasia versus other types of carcinoma (Fig. 1C), (13) carcinoma with osseous metaplasia versus other types of carcinoma, and (14) carcinosarcoma versus other types of carcinoma (Fig. 1E). The following 7 histologic features of MPCs metastasizing in lymph nodes were evaluated: (1) histologic grade (1, 2, 3; only for

carcinoma component) [20], (2) extranodal invasion (absent, present), (3) squamous cell carcinoma in lymph node-metastatic tumors (absent, present) (Fig. 1D), (4) adenocarcinoma with spindle cell differentiation in lymph node-metastatic tumors (absent, present), (5) adenosquamous cell carcinoma in lymph node-metastatic tumors (absent, present), (6) carcinosarcoma in lymph node-metastatic tumors (absent, present), and (7) tumor stroma in lymph node-metastatic tumors (none, mild, moderate, severe). *Extranodal invasion* was defined as the extension of tumor cells through the capsule of at least one lymph node into the perinodal adipose tissue. Nuclear atypia, structural atypia, and the number of mitotic figures were evaluated in the same manner as for the primary invasive tumors.

One author (N. O.) assessed all the characteristics of the primary tumors and the nodal metastatic tumors, and another author (T. H.) identified the characteristics of all the IDCs to confirm the tumor cell characteristics in these tumor components recorded by N. O. without knowledge of the outcome of the patients with MPC. Whenever a discrepancy occurred, the authors reexamined the slides to reach a consensus.

2.5. Immunohistochemistry

We used the immunohistochemistry records for estrogen receptor (ER), progesterone receptor (PR), and HER2 for the IDCs, ILCs, and MPCs diagnosed by 2 or 3 pathologists at the time of routine examination. A tumor with nuclear staining for ER or PR in 10% or more of its tumor cells was assessed as ER-positive or PR-positive. HER2 cell membrane expression was categorized as follows: (1) HER2 category 0, negative; (2) HER 2 category 1, weakly positive (faintly stained cell membrane and $\leq 10\%$ of overall tumor area); (3) HER2 category 2, moderately positive (moderately stained cell membrane and $>10\%$ of overall tumor area); and (4) HER2 category 3, strongly positive (strongly stained cell membrane and $>10\%$ of overall tumor area). Tumors classified as HER2 category 0 or 1 were considered negative for HER2 expression. All the MPCs were immunohistochemically studied using commercially available monoclonal antibodies to keratins (AE1/3) (Fig. 1F) and vimentin (Fig. 1G) and were confirmed to be positive for both keratins and vimentin.

2.6. Patient outcome and statistical analysis

Survival was evaluated using a median follow-up period of 153 months (range, 1-304 months) until February 2007. Of the 6138 IDC patients, 1019 developed tumor recurrences; and 771 died of their disease. Of the 302 ILC patients, 55 developed tumor recurrences; and all of them died of their disease. Of the 46 MPC patients, 15 developed tumor recurrences; and 11 died of their disease. The recurrence-free and overall survival periods were determined

beginning at the time of surgery. Tumor relapse was considered to have occurred whenever evidence of metastasis was first observed.

The χ^2 test was used to analyze whether significant differences existed in the frequencies of the clinicopathologic factors among the patients with IDC, ILC, or MPC.

We analyzed the outcome predictive power of tumor histology (IDC, ILC, MPC) and clinicopathologic factors for tumor recurrence and tumor-related death using multivariate analyses performed according to the Cox proportional hazard regression model as follows: model 1 included tumor histology, age, invasive tumor size, skin invasion, lymphatic invasion, blood vessel invasion, and nodal status; and model 2 included the above 7 factors plus neoadjuvant therapy, adjuvant therapy, ER/PR expression, and HER2 expression.

For the MPCs, the 14 histologic factors examined in the primary MPCs plus the 7 histologic factors examined in the MPCs located in the lymph nodes as well as age, neoadjuvant therapy, adjuvant therapy, and HER2 expression were entered into the univariate analyses; the factors that were significantly associated with tumor recurrence or tumor-related death were then entered into the multivariate analyses performed using the Cox proportional hazard regression model.

The multivariate analyses were performed using a case-wise and step-down method that was applied until all the remaining factors were significant at a P value $< .05$. Survival curves were drawn using the Kaplan-Meier method. All the analyses were performed using Statistica/Windows software (StatSoft, Tulsa, OK).

3. Results

3.1. Univariate analyses of factors with significant differences among patients with IDC, ILC, or MPC

Patients with MPC showed significantly lower frequencies of neoadjuvant therapy, adjuvant therapy, and lymph vessel invasion than patients with IDC or ILC and a significantly higher frequency of skin invasion than patients with IDC (Table 1). Furthermore, all the patients with MPC exhibited negative immunostaining for ER and PR. Patients with ILC were significantly older than patients with IDC or MPC and had a significantly larger tumor size, a significantly lower HER2 category, and a significantly lower frequency of lymph vessel invasion than patients with IDC (Table 1). No significant differences in any other factor were observed among the 3 groups.

3.2. Multivariate analyses of outcome among patients with IDC, ILC, or MPC

In model 1 and model 2, the patients with MPC had significantly higher hazard rates (HRs) for tumor recurrence

(model 1: HR, 5.5; 95% confidence interval [CI], 3.2-9.6; model 2, HR, 6.6; 95% CI, 2.5-17.1) and tumor death (model 1: HR, 4.2; 95% CI, 2.2-8.1; model 2, HR, 12.4; 95% CI, 3.2-46.2) (Fig. 2A) than the patients with IDC in the multivariate analyses, although no significant differences in the HRs for tumor recurrence and tumor death were observed between patients with IDC and those with ILC in the multivariate analyses (data not shown). Furthermore, the patients with MPC had significantly higher HRs for tumor recurrence and tumor death than the patients with IDC independent of nodal metastasis in the multivariate analyses (Table 2). No significant differences in the HRs for tumor recurrence and tumor death were observed between patients with IDC and those with ILC among patients with or without nodal metastasis in the multivariate analyses (Table 2). Meanwhile, among patients not older than 39 years, the patients with MPC had

significantly higher HRs for tumor recurrence and tumor death in model 1 of the multivariate analysis (Table 3); but model 2 could not be examined because of the small numbers of patients with ILC (2 cases) and MPC (3 cases). In patients with triple-negative carcinomas, the patients with MPC and the patients with ILC had significantly higher HRs for tumor recurrence and tumor death than the patients with IDC in multivariate analyses (Table 3).

3.3. Outcome predictive factor for patients with MPC

A patient age not exceeding 39 years (Fig. 2C), the use of neoadjuvant therapy, the presence of skin invasion (Fig. 2B), the presence of squamous cell carcinoma in a lymph node (Fig. 2D), and the International Union Against Cancer




Fig. 2 Overall survival curves. A, Patients with MPC show a significantly shorter overall survival period than patients with IDC and patients with ILC, and no significant difference in overall survival period is present between patients with IDC and patients with ILC. B, MPC patients with skin invasion show a significantly shorter overall survival period than those without skin invasion. C, MPC patients 39 years and younger show a significantly shorter overall survival period than those older than 39 years. D, MPC patients with squamous cell carcinoma in lymph nodes show a significantly shorter overall survival period than those without nodal metastasis or those with nodal metastasis but with no squamous cell carcinoma in their lymph nodes.

Table 2 Multivariate analyses for tumor recurrence and tumor-related death in patients with IDC, ILC, or MPC according to nodal status

No. of patients (%)					
Model 1					
<i>Patients without nodal metastasis (n = 3915)</i>					
	Tumor recurrence			Tumor-related death	
	Cases	Cases	HR (95% CI) P value	Cases	HR (95% CI) P value
IDC	3703	403 (11)	Referent	261 (7)	Referent
ILC	183	22 (12)	1.2 (0.7-2.1) .425	12 (7)	1.0 (0.5-2.0) .943
MPC	29	7 (24)	6.0 (2.8-12.9) <.001	4 (14)	3.5 (1.3-9.8) .016
<i>Patients with nodal metastasis (n = 2558)</i>					
IDC	2424	614 (25)	Referent	510 (21)	Referent
ILC	119	33 (28)	1.2 (0.8-1.9) .336	29 (25)	1.3 (0.9-2.0) .163
MPC	15	7 (47)	4.9 (2.3-10.5) <.001	7 (47)	4.0 (1.8-9.2) <.001
Model 2					
<i>Patients without nodal metastasis (n = 1852)</i>					
IDC	1737	163 (9)	Referent	42 (2)	Referent
ILC	101	10 (10)	1.2 (0.6-2.4) .690	3 (7)	1.4 (0.4-4.6) .627
MPC	14	4 (29)	5.2 (1.2-22.7) .028	4 (29)	4.4 (1.2-15.9) .023
<i>Patients with nodal metastasis (n = 412)</i>					
IDC	391	94 (24)	Referent	30 (8)	Referent
ILC	16	5 (31)	2.0 (0.7-5.9) .187	3 (19)	3.0 (0.7-13.9) .164
MPC	5	3 (60)	8.6 (2.3-32.9) .001	3 (60)	28.9 (4.6-123.5) <.001

NOTE. Patients without nodal metastasis—Model 1 (tumor recurrence and tumor-related death): adjusted for tumor histology, age, skin invasion, lymphatic invasion, blood vessel invasion, and tumor size. Model 2 (tumor recurrence and tumor-related death): adjusted for the above factors (in model 1) as well as neoadjuvant therapy, adjuvant therapy, HER2 category, and ER and PR statuses. Patients with nodal metastasis—Model 1 (tumor recurrence and tumor-related death): adjusted for tumor histology, age, skin invasion, lymphatic invasion, blood vessel invasion, and tumor size. Model 2 (tumor recurrence and tumor-related death): adjusted for the above factors (in model 1) as well as neoadjuvant therapy, adjuvant therapy, HER2 category, and ER and PR statuses.
Abbreviation: n, number of cases that were examined in the multivariate analyses.

(UICC) pTNM stage were significantly associated with tumor recurrence and tumor-related death in the univariate analyses (Table 4). A tumor necrosis percentage of more than 30% of the primary tumors, the UICC pN category, the histologic grade of the tumors in the lymph nodes, the presence of extranodal invasion, the presence of adenocarcinoma with spindle cell differentiation in tumors in the

lymph nodes, and the presence of tumor stroma in tumors in the lymph nodes were significantly associated with tumor-related death in the univariate analyses (Table 4). Other clinicopathologic factors, including MPC subtype, were not significantly associated with tumor recurrence or tumor death in the univariate analyses (Table 4).

In the multivariate analyses, the presence of skin invasion and an age not exceeding 39 years significantly increased the HRs for tumor recurrence and tumor death, whereas the presence of squamous cell carcinoma in tumors in the lymph nodes significantly increased the HR for tumor death (Table 5).

4. Discussion

In this study, none of the MPCs was positive for ER and PR; and only one MPC was positive for HER2. Furthermore, the presence of lymph vessel invasion, the presence of blood vessel invasion, and the UICC pN status did not exhibit any prognostic significance in patients with MPC, confirming the results of previous studies [7,9,14]. Because these factors are well-known outcome predictors

Table 3 Multivariate analyses for tumor recurrence and tumor-related death in patients with IDC, ILC, or MPC according to age and triple-negative status

No. of patients (%)					
Model 1 (n = 674)					
<i>Patients ≤39 y old</i>					
	Tumor recurrence			Tumor-related death	
	Cases	Cases	HR (95% CI) P value	Cases	HR (95% CI) P value
IDC	654	159 (24)	Referent	114 (17)	Referent
ILC	15	2 (13)	1.0 (0.3-6.3) .952	1 (7)	0.7 (0.1-5.0) .712
MPC	6	4 (67)	32.4 (11.1-99.2) <.001	4 (67)	55.5 (17.1-173.5) <.001
<i>Patients whose carcinomas were negative for ER, PR, and HER2 (triple-negative IDC) (n = 304)</i>					
IDC	271	42 (16)	Referent	19 (7)	Referent
ILC	14	4 (29)	3.6 (1.2-11.1) .023	2 (14)	4.6 (0.9-21.9) .059
MPC	19	6 (32)	9.4 (1.8-15.0) .002	3 (16)	5.1 (1.3-19.4) .017

NOTE. Patients not older than 39 years—Model 1: adjusted for tumor histology, skin invasion, lymphatic invasion, blood vessel invasion, tumor size, and nodal status. Triple-negative IDC patients—Tumor recurrence: adjusted for tumor histology, age, skin invasion, lymphatic invasion, and nodal status. Tumor-related death: adjusted for tumor histology, age, skin invasion, and nodal status.
Abbreviation: n, number of cases that were examined in the multivariate analyses.

Table 4 Association of clinicopathologic factors with tumor recurrence and tumor-related death in patients with MPC

Factors	Cases 46	No. of patients (%)		P value	Cases with tumor-related death		P value
		Cases with tumor recurrence					
Age, y							
≤39	6	4	(67)	.009	4	(67)	.007
>39	40	11	(28)		7	(18)	
Neoadjuvant therapy							
No	42	11	(26)	<.001	8	(19)	.002
Yes	4	4	(100)		3	(75)	
Adjuvant therapy							
No	37	10	(27)	.505	7	(19)	.474
Yes	9	5	(56)		4	(44)	
Invasive tumor size (mm)							
≤20	13	3	(23)	.352	1	(8)	.072
>20 to ≤50	26	9	(35)		7	(27)	
>50	7	3	(43)		3	(43)	
Skin invasion							
Absent	39	9	(20)	<.001	6	(13)	<.001
Present	7	6	(86)		5	(71)	
Histologic grade							
Grade 1	1	0		.558	0		NA
Grade 2	5	1	(20)		0		
Grade 3	40	14	(35)		11	(28)	
No. of mitotic figures in 10 high-power fields.							
≤32	24	8	(33)	.878	5	(21)	.483
>32	22	7	(32)		6	(27)	
Lymph vessel invasion							
Absent	41	12	(29)	.398	9	(22)	.498
Present	5	3	(60)		2	(40)	
Blood vessel invasion							
Absent	45	15	(33)	NA	11	(24)	NA
Present	1	0			0		
Area (%) occupied by of tumor necrosis within the tumor							
Absent/≤30	38	11	(29)	.119	7	(18)	.031
>30	8	4	(50)		4	(50)	
Types of MPC							
Epithelial	34	12	(35)	.813	8	(24)	.828
Mixed	12	3	(25)		3	(25)	
Squamous cell carcinoma vs other types of carcinoma							
Squamous	7	4	(57)	.134	3	(43)	.136
Other types	39	11	(28)		8	(21)	
Adenocarcinoma with spindle cell differentiation vs other types of carcinoma							
Adenoca with spindle	8	4	(50)	.422	2	(25)	.938
Other types	38	11	(29)		9	(23)	
Adenosquamous carcinoma vs other types of carcinoma							
Adenosquamous ca	19	4	(21)	.150	3	(16)	.264
Other types	27	11	(41)		8	(30)	
Carcinoma with chondroid metaplasia vs other types of carcinoma							
Ca with chondroid	4	1	(25)	.659	1	(25)	.835
Other types	42	14	(33)		10	(24)	
Carcinoma with osseous metaplasia vs other types of carcinoma							
Ca with osseous	1	0		NA	0		NA
Other types	45	15	(33)		11	(24)	
Carcinosarcoma vs other types of carcinoma							
Carcinosarcoma	7	2	(29)	.660	2	(29)	.432
Other types	39	13	(33)		9	(23)	

(continued on next page)

Table 4 (continued)

Factors	Cases	No. of patients (%)		P value	Cases with tumor-related death		P value
	46	Cases with tumor recurrence					
UICC pN category (n = 44)							
N0	29	7	(24)	.255	4	(14)	.049
N1	11	4	(36)		4	(36)	
N2	2	2	(100)		2	(100)	
N3	2	1	(50)		1	(50)	
Histologic grade of lymph node-metastatic tumors (n = 44)							
N0	29	7	(24)	.195	4	(14)	.032
Grade 1	1	0			0		
Grade 2	2	1	(50)		1	(50)	
Grade 3	12	6	(50)		6	(50)	
Extranodal invasion of lymph node-metastatic tumors (n = 44)							
N0	29	7	(24)	.214	4	(14)	.035
Absent	7	3	(43)		3	(43)	
Present	8	4	(50)		4	(50)	
Squamous cell carcinoma in lymph node-metastatic tumors (n = 44)							
N0	29	7	(24)	.024	4	(14)	.002
Absent	10	3	(30)		3	(30)	
Present	5	4	(80)		4	(80)	
Adenocarcinoma with spindle cell differentiation in lymph node-metastatic tumors (n = 44)							
N0	29	7	(24)	.159	4	(14)	.020
Absent	14	6	(43)		6	(43)	
Present	1	1	(100)		1	(100)	
Adenosquamous carcinoma in lymph node-metastatic tumors (n = 44)							
N0	29	7	(24)	.554	4	(14)	.163
Absent	12	6	(50)		6	(50)	
Present	3	1	(33)		1	(33)	
Carcinosarcoma in lymph node-metastatic tumors (n = 44)							
N0	29	7	(24)	.610	4	(14)	.199
Absent	13	7	(54)		7	(54)	
Present	2	0			0		
Tumor stroma in lymph node-metastatic tumors (n = 44)							
N0	29	7	(24)	.061	4	(14)	.032
None	7	3	(42)		3	(43)	
Mild	1	1	(100)		1	(100)	
Moderate	3	0			0		
Severe	2	2	(100)		2	(100)	
UICC pTNM stage (n = 44)							
I	11	2	(18)	.044	0		.003
IIA	16	4	(25)		3	(19)	
IIB	6	2	(33)		2	(33)	
IIIA	4	1	(25)		1	(25)	
IIIB	5	4	(80)		4	(80)	
IIIC	2	1	(50)		1	(50)	

Abbreviations: NA, not available; Squamous, squamous cell carcinoma; Adenoca with spindle, adenocarcinoma with spindle cell differentiation; Adenosquamous ca, adenosquamous carcinoma; Ca with chondroid, carcinoma with chondroid metaplasia; Ca with osseous, carcinoma with osseous metaplasia; pN, pathologic regional lymph node; N0, no nodal metastasis; N1, 1 to 3 nodal metastases; N2, 4 to 9 nodal metastases; N3, 10 or more nodal metastases; pTNM, pathologic TNM.

for patients with IDC or patients with ILC, these findings strongly suggest that the biological characteristics of MPCs are quite different from those of IDCs or ILCs [16,21-25]. Four previous studies have investigated whether a significant difference in the survival period exists between

patients with MPC and those with IDC [8,15,18,19]. The statistical analyses for survival in these studies, which produced controversial results regarding the survival of patients with MPC, were performed using a matched control case analysis, not a consecutive case analysis; and

Table 5 Multivariate analyses for tumor recurrence and tumor-related death in patients with MPC

	Tumor recurrence		Tumor-related death	
	HRs 95% CI	P value	HRs 95% CI	P value
Skin invasion				
Absent	Referent		Referent	
Present	24.8 5.4-112.1	<.001	39.1 5.0-309.2	<.001
Age, y				
>39	Referent		Referent	
≤39	14.1 3.1-65.3	<.001	34.4 4.4-269.9	<.001
Squamous cell carcinoma in lymph node-metastatic tumors				
N0 and absent	Referent		Referent	
Present	2.2 0.9-5.3	.087	5.6 1.6-19.4	.006

NOTE. Tumor recurrence: adjusted for skin invasion, age, neoadjuvant therapy, and squamous cell carcinoma in lymph node-metastatic tumors. Tumor-related death: adjusted for skin invasion, age, squamous cell carcinoma in lymph node-metastatic tumors, neoadjuvant therapy, occupied area of tumor necrosis, UICC pN category, histologic grade of lymph node-metastatic tumors, extranodal invasion, adenocarcinoma with spindle cell differentiation in lymph node-metastatic tumors, and tumor stroma in lymph node-metastatic tumors.

the periods during which the patients with MPC and the patients with IDC were operated on also differed [8]. The results of the present study were obtained using consecutive cases treated during the same period; our findings clearly demonstrated that MPCs are associated with a significantly higher rate of tumor recurrence or tumor death than IDCs or ILCs, independent of the nodal status, age not exceeding 39 years, adjuvant therapy status, or neoadjuvant therapy status. Thus, we can conclude that MPCs have a greater malignant biological potential than IDCs or ILCs. Furthermore, the triple-negative MPCs observed in this study had more aggressive characteristics than the triple-negative IDCs and the triple-negative ILCs, whereas the triple-negative ILCs had greater malignant biological characteristics than the triple-negative IDCs; these findings strongly suggest that studies on outcome predictors or targeted therapies for triple-negative breast carcinoma should be performed according to the specific type of triple-negative breast carcinoma. Because some genes are selectively expressed in patients with MPC but not in patients with other types of breast carcinomas [13,16,24,25], the development of neoadjuvant therapy or adjuvant therapy targeting such genes may improve the outcome of patients with MPC.

At the beginning of this study, we speculated that the MPC type, such as epithelial versus mixed or squamous versus others, might be significantly associated with the outcome of patients with MPC. However, the results of this

study clearly demonstrated that the MPC subtype had no significant effect on the outcome of patients with MPC, confirming the results of previous studies [8,11,13,26]; instead, the most important outcome predictors for patients with MPC were the presence of skin invasion, an age not exceeding 39 years, and the presence of a squamous cell carcinoma component in tumors in the lymph nodes. Consequently, these 3 factors appear to be important prognostic factors for patients with MPC; and the results of this study confirm that the WHO classification for MPC, which contains both epithelial and mixed types of MPC [1], is a reasonable classification for patients with MPC from the viewpoint of patient outcome. Because of the relatively small number of cases of each MPC subtype, however, this study was unable to investigate whether important clinicopathologic predictors of outcome exist for specific MPC subtypes, such as low-grade adenosquamous carcinoma versus high-grade adenosquamous carcinoma and fibromatosis-like low-grade carcinosarcoma versus high-grade carcinosarcoma. Therefore, the clinicopathologic outcome predictors for each MPC subtype should be separately investigated in the future.

References

- [1] Tavassoli FA, Devilee P, et al. The WHO classification of tumors. Pathology and genetics of tumours of the breast and female genital organs; 2003.
- [2] Kaufman MW, Marti JR, Gallar HS, et al. Carcinoma of the breast with pseudosarcomatous metaplasia. *Cancer* 1984;53:1908.
- [3] Oberman HA. Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. *Am J Surg Pathol* 1987;11:918-29.
- [4] Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. I. Matrix-producing carcinoma. *HUM PATHOL* 1989;20:628-35.
- [5] Wargotz ES, Deoes PH, Norris HJ. Metaplastic carcinomas of the breast. II. Spindle cell carcinoma. *HUM PATHOL* 1989;20:732-40.
- [6] Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. III. Carcinosarcoma. *Cancer* 1989;64:1490-9.
- [7] Wargotz ES, Norris HJ. Metaplastic carcinomas of the breast. IV. Squamous cell Carcinoma. *Cancer* 1990;65:272-6.
- [8] Chhieng C, Cranor M, Lesser ME, et al. Metaplastic carcinoma of the breast with osteocartilaginous heterologous elements. *Am J Surg Pathol* 1998;22:188-94.
- [9] Rayson D, Adjei AA, Suman VJ. Metaplastic breast cancer: prognosis and response to systemic therapy. *Ann Oncol* 1999;10:413-9.
- [10] Chao TC, Wang CS, Chen SC. Metaplastic carcinomas of the breast. *J Surg Oncol* 1999;71:220-5.
- [11] Kurian KM, Al-Nafussi A. Sarcomatoid/metaplastic carcinoma of the breast: a clinicopathological study of 12 cases. *Histopathology* 2002;40:58-64.
- [12] Lien HC, Lin CW, Mao TL, et al. p53 overexpression and mutation in metaplastic carcinoma of the breast: genetic evidence for a monoclonal origin of both the carcinomatous and the heterogenous sarcomatous components. *J Pathol* 2004;204:131-9.
- [13] Reis-Filho JS, Pinheiro C, Lambros MBK, et al. EGFR amplification and lack of activating mutations in metaplastic breast carcinomas. *J Pathol* 2006;209:445-53.
- [14] Dave G, Cosmatos H, Do T. Metaplastic carcinoma of the breast: a retrospective review. *Int J Radiation Oncol Biol Phys* 2006;64:771-5.
- [15] Luini A, Aguilar M, Gatti G. Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European

- Institute of Oncology and review of the literature. *Breast Cancer Res Treat* 2007;101:349-53.
- [16] Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. *Oncogene* 2007;26:7859-71.
- [17] Hayes MJ, Thomas D, Emmons A, et al. Genetic changes of Wnt pathway genes are common events in metaplastic carcinomas of the breast. *Clin Cancer Res* 2008;14:4038-44.
- [18] Downs-Kelly E, Naycemuddin KM, Albarracin C, et al. Matrix-producing carcinoma of the breast. An aggressive subtype of metaplastic carcinoma. *Am J Surg Pathol* 2009;33:534-41.
- [19] Beatty JD, Atwood M, Tickman R, et al. Metaplastic breast cancer: clinical significance. *Am J Surg* 2006;191:567-664.
- [20] Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer. *Br J Cancer* 1957;11:359-77.
- [21] Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. *Ann Surg Oncol* 2007;14:166-73.
- [22] Koker MM, Kleer CG. p63 expression in breast cancer. A highly sensitive and specific marker of metaplastic carcinoma. *Am J Surg Pathol* 2004;28:1506-12.
- [23] Carpenter PM, Wang-Rodriguez J, Chan OTM, et al. Laminin 5 expression in metaplastic breast carcinomas. *Am J Surg Pathol* 2008;32:345-53.
- [24] Weigelt B, Kreike B, Reis-Filho JS. Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. *Breast Cancer Res Treat* 2009;117:273-80.
- [25] Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. *Cancer Res* 2009;69:4116-24.
- [26] Gobbi H, Simpson JF, Borowsky A, et al. Metaplastic breast tumors with a dominant fibromatosis-like phenotype have a high risk of local recurrence. *Cancer* 1999;85:2170-82.

p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci in invasive ductal carcinoma of the breast

Takahiro Hasebe¹, Motoki Iwasaki², Sadako Akashi-Tanaka³, Takashi Hojo³, Tatsuhiro Shibata⁴, Yuko Sasajima⁵, Takayuki Kinoshita³ and Hitoshi Tsuda⁵

¹Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Service, National Cancer Center, Chuo-ku, Tokyo, Japan; ²Epidemiology and Prevention Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Chuo-ku, Tokyo, Japan; ³Department of Breast Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan; ⁴Cancer Genomics Project, National Cancer Center Research Institute, Chuo-ku, Tokyo, Japan and ⁵Clinical Laboratory Division, National Cancer Center Hospital, Chuo-ku, Tokyo, Japan

The purpose of this study was to determine whether p53 protein expression in tumor-stromal fibroblasts forming fibrotic foci is a significant outcome predictor, similar to p53 protein expression in tumor-stromal fibroblasts not forming fibrotic foci, and whether the combined assessment of p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci served as an important outcome predictor among 1039 patients with invasive ductal carcinoma of the breast. We analyzed the outcome predictive power of the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci using multivariate analyses with well-known clinicopathological factors. The Allred score risk classifications for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci were superior to the Allred scores for p53 in tumor-stromal fibroblasts not forming fibrotic foci alone for accurately predicting the tumor-related death of patients with invasive ductal carcinoma when examined using multivariate analyses. The Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci significantly increased the hazard rates for tumor recurrence and tumor-related death independent of the UICC pTNM stage in the multivariate analyses. These results indicated that the Allred score risk classification based on the combined assessment of p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci is a very useful outcome predictor among patients with invasive ductal carcinoma.

Modern Pathology (2010) 23, 662–672; doi:10.1038/modpathol.2010.47; published online 5 March 2010

Keywords: fibroblast; fibrotic focus; p53; tumor cell–stromal cell interaction; breast

Along with others, we have already reported that a fibrotic focus, a characteristic histological feature of tumor stroma, is a very useful histological tumor-stromal indicator for accurately predicting the outcome of patients with invasive ductal carcinoma (IDC),^{1–5} and the proliferative activity of tumor-

stromal fibroblasts forming and not forming fibrotic foci has a very important function in nodal metastasis and distant organ metastasis by IDCs.^{6,7} Because it has recently been reported that the gene expression profile and protein expression profile of the tumor stroma have a very important function in tumor progression in carcinoma^{8,9} and that the interactions between tumor cells and stromal cells also are very important in tumor progression in carcinomas,^{10,11} these findings strongly suggest that the tumor stroma has a significant function in tumor progression in IDCs. Mutations of the p53 tumor suppressor gene have been described in the stromal fibroblasts of breast and prostate carcinomas in

Correspondence: Dr T Hasebe, MD, PhD, Pathology Consultation Service, Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.

E-mail: thasebe@ncc.go.jp

Received 23 December 2009; revised and accepted 28 January 2010; published online 5 March 2010

humans and experimental animals,^{12–14} and p53 mutations in breast cancer stromal cells have been reported to be closely associated with nodal metastasis.¹⁵ However, some studies have reported that p53 mutations are not observed in the tumor stroma of breast cancer,^{16,17} and the possibility of technical problem, eg polymerase chain reaction artifacts for the p53 gene abnormality, has been suggested by Campbell *et al*.¹⁸ We recently showed that p53 expression in tumor-stromal fibroblasts not forming fibrotic foci was a very important outcome predictor for IDC patients who had or had not received neoadjuvant therapy.^{19,20} On the basis of the above findings, the p53 status of tumor-stromal fibroblasts not forming fibrotic foci probably has a very important function in tumor progression in IDCs.

We also previously reported that our newly devised grading system for lymph vessel tumor emboli is a very useful histological grading system for accurately predicting the outcome of patients with IDC who have not received neoadjuvant therapy; furthermore, this grading system can be used to classify the prognosis of IDC patients with lymph vessel invasion into low-risk, intermediate-risk, and high-risk groups.²¹ In addition, we recently confirmed that this grading system for lymph vessel tumor emboli was a very important outcome predictor for patients with IDC in a different patient group.²²

The purpose of this study was to determine whether the combined assessment of p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci served as an important outcome predictor among patients with IDC of the breast using multivariate analyses with well-known prognostic factors and our grading system for lymph vessel tumor emboli. The results indicated that a score classification based on the combined assessment of p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci was a very useful outcome predictor among patients with IDC of the breast.

Materials and methods

Cases

The subjects of this study were 1039 consecutive patients with IDC of the breast who did not receive neoadjuvant therapy and who were surgically treated at the National Cancer Center Hospital between January 2000 and December 2005 (almost the same case series as that used in our previous study).^{19,22} The IDCs were diagnosed preoperatively using needle biopsy, aspiration cytology, a mammography, or ultrasonography. All the patients were Japanese women, ranging in age from 23 to 72 years (median, 55 years). All had a solitary lesion; 497 patients were premenopausal and 542 were postmenopausal. A partial mastectomy had been performed in 455 patients, and a modified radical

mastectomy had been performed in 584. A level I and level II axillary lymph node dissection had been performed in all the patients, and a level III axillary lymph node dissection had been performed in some of the patients with IDC.

Of the 1039 patients, 873 received adjuvant therapy, consisting of chemotherapy in 218 patients, endocrine therapy in 281 patients, and chemotherapy in 374 patients. The chemotherapy regimens used were anthracycline-based with or without taxane and non-anthracycline-based, and the endocrine therapy regimens consisted of tamoxifen with or without a gonadotropin-releasing hormone agonist, tamoxifen, with or without an aromatase inhibitor, an aromatase inhibitor alone, or a gonadotropin-releasing hormone agonist alone. No cases of inflammatory breast cancer were included in this series. All the tumors were classified according to the pathological UICC-TNM (pTNM) classification.²³ The protocol of this study (20-112) was reviewed by the institutional review board of the National Cancer Center.

For the pathological examination, we fixed the surgically resected specimens in 10% formalin, and the size and gross appearance of the tumors were recorded. The tumor size was confirmed by comparison with the tumor size on the histological slides; if more than one invasive focus was present, the size of the largest invasive focus was recorded as the invasive tumor size, based on a previously reported definition for determining the size of microinvasion in IDC with multiple microinvasive foci²³ in this study.

Histological Examination

Serial sections of each tumor area were cut from paraffin blocks. One section from each tumor was stained with hematoxylin and eosin and was examined histologically to confirm the diagnosis, and another section was subjected to immunohistochemistry. The following eight histological factors and the grading system for lymph vessel tumor emboli^{21,22} were evaluated: (1) invasive tumor size (≤ 20 , > 20 to ≤ 50 , > 50 mm); (2) histological grade (1, 2, 3);²⁴ (3) tumor necrosis (absent, present);²⁵ (4) fibrotic focus (absent, fibrotic focus diameter ≤ 8 mm, fibrotic focus diameter > 8 mm) (Figure 1);^{1,2} (5) blood vessel invasion (absent, present); (6) adipose tissue invasion (absent, present); (7) skin invasion (absent, present); and (8) muscle invasion (absent, present).

Immunohistochemistry

Immunohistochemical staining for estrogen receptors, progesterone receptors, p53, and HER2 products was performed using an autoimmunostainer (Optimax Plus; BioGenex, San Ramon, CA, USA). The antigen retrieval device for Optimax Plus was




Figure 1 Invasive ductal carcinomas with fibrotic foci (a–d). (a) A fibrotic focus measuring 6.4×3.3 mm is visible within the tumor (panoramic view, arrows). The fibrotic focus shows a scar-like feature and is surrounded by invasive ductal carcinoma cells. (b) The fibrotic focus area consists mainly of fibroblasts arranged in a storiform pattern. (c) A fibrotic focus measuring 10.2×7.3 mm is visible within the tumor (panoramic view, arrows). The fibrotic focus has a fibrosclerotic core and is surrounded by invasive ductal carcinoma cells. Small residual tumor islands are present within the fibrotic focus. (d) The fibrotic focus consists of fibroblasts and hyalinized collagen fibers in a storiform arrangement.

an autoclave, and each specimen was immersed in citrate buffer and incubated at 121°C for 10 min. Immunoperoxidase staining was performed using a labeled streptavidin biotin staining kit (BioGenex) according to the manufacturer's instructions. The antibodies used were the anti-estrogen receptor mouse monoclonal antibody ER88 (BioGenex), the anti-progesterone receptor mouse monoclonal anti-

body PR88 (BioGenex), the anti-HER2 mouse monoclonal antibody CB11 (BioGenex), and the p53 mouse monoclonal antibody DO7 (Dako, Glostrup, Denmark). ER88, PR88, and CB11 were previously diluted, and DO7 was applied at a dilution of 1:100. After immunostaining, the sections were counterstained with hematoxylin. Sections of the IDCs that were positive for estrogen receptor, progesterone

receptor, HER2, and p53 were used each time as a positive control. As a negative control, the primary antibody was replaced with normal mouse immunoglobulin.

Assessment of ER, PR, p53, and HER2 Expression

Slides of the tumor cells immunostained for estrogen receptor, progesterone receptor, and p53 were scored using the Allred scoring system, as described previously,^{26–28} and the Allred scores for estrogen receptor, progesterone receptor, and p53 expression in the tumor cells were classified into the following three categories¹⁹: (1) Allred score for estrogen receptor in tumor cells (0 or 2, 3–6, and 7 or 8); (2) Allred score for progesterone receptor in tumor cells (0 or 2, 3–6, and 7 or 8); and (3) Allred scores for p53 in tumor cells (0 or 2 or 3, 4–6, and 7 or 8). We modified the Allred scoring system to assess the nuclear expression of p53 in the tumor-stromal fibroblasts forming and not forming fibrotic foci,^{19,20} and the Allred scores for p53 expression in tumor-stromal fibroblasts forming and not forming fibrotic foci were classified into the following categories: (1) Allred scores for p53 in tumor-stromal fibroblasts forming fibrotic foci (0, 2, 3, and 4–8); and (2) Allred scores for p53 in tumor-stromal fibroblasts not forming fibrotic foci (0 or 2, 3, and 4–8) (Figures 2 and 3). Of the 1039 IDCs, 373 IDCs had fibrotic foci; we could not assess the Allred scores for p53 in tumor-stromal fibroblasts forming a fibrotic focus in 97 of the 373 IDCs with fibrotic foci because the immunohistochemistry examinations for these specimens were performed using tumor tissue sections that did not contain a fibrotic focus at the time of routine examination. The HER2 status of the tumor cells was semiquantitatively scored on a scale of 0–3 according to the level of HER2 protein expression,²⁹ and it was classified into three categories: 0 or 1, 2, and 3.

Invasive ductal carcinoma with a fibrotic focus




Figure 2 Schematic illustration of an invasive ductal carcinoma with a fibrotic focus.

Patient Outcome and Statistical Analysis

Survival was evaluated using a median follow-up period of 52 months (range: 18–102 months) until February 2009. Of the 1039 IDC patients, 910 patients were alive and well, 129 had developed tumor recurrences, and 58 had died of their disease. The tumor recurrence-free survival and overall survival periods were calculated using the time of surgery as the starting point. Tumor relapse was considered to have occurred whenever evidence of metastasis was found.

The Mann–Whitney test was used to compare the Allred scores for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci, and the correlation analyses were performed using Cochran–Mantel–Haenszel statistics.

We analyzed the outcome predictive power of the eight histological factors, the grading system for lymph vessel tumor emboli;^{21,22} the Allred scores for estrogen receptor; progesterone receptor, and p53 in tumor cells; the category of HER2 expression in tumor cells; the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci, adjuvant therapy (yes or no); age (≤ 39 years and > 39 years); and the UICC-pathological nodal status (N factor, ie, no nodal metastasis, N0; 1–3 nodal metastases, N1; 4–9 nodal metastases, N2; and 10 or more nodal metastases, N3)²³ for tumor recurrence, and tumor-related death in univariate analyses using the Cox proportional hazard regression model. The factors significantly associated with outcome in the univariate analyses were then entered together into the multivariate analyses using the Cox proportional hazard regression model according to the UICC pTNM stage. The case-wise and step-down method was applied until all the remaining factors were significant at a *P*-value of below 0.05. Because fewer than 10 tumor-related deaths occurred among the UICC stage I IDC patients (Table 2), it was impossible to perform multivariate analyses for tumor-related death in this group. All the analyses were performed using Statistica for Windows software (StatSoft, Tulsa, OK, USA).






Results

Allred Scores for p53 in Tumor-Stromal Fibroblasts Forming and Not Forming Fibrotic Foci

Although a significant association was observed between the Allred scores for p53 in tumor-stromal fibroblasts forming and those not forming fibrotic foci ($P < 0.001$; Figure 4a), the latter value (mean value, 2.2; standard deviation, 2.1) was significantly higher than the former (mean value, 1.6; standard deviation, 2.0; $P = 0.001$). The Allred scores for p53 in tumor-stromal fibroblasts forming fibrotic foci were also significantly associated with the fibrotic focus diameter, and in IDCs with a fibrotic focus

diameter >8 mm, the number of IDCs with Allred scores of 4–8 for p53 in tumor-stromal fibroblasts forming fibrotic foci was larger than that of

IDCs with Allred scores of 0, 2, or 3 in tumor-stromal fibroblasts forming fibrotic foci (Figure 4b).



Allred Score Risk Classification for p53 in Tumor-Stromal Fibroblasts Forming and not Forming Fibrotic Foci in Patients with Invasive Ductal Carcinoma with and without Fibrotic Foci

We devised an Allred score risk classification for p53 in tumor-stromal fibroblasts in IDCs based on the combined Allred scores for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci (Table 1). This classification was successfully used to classify IDC patients with or without fibrotic foci into three risk classes (low risk, intermediate risk, and high risk) according to the ratios for tumor recurrence and tumor-related death (Table 2; Figure 5). Among the UICC pTNM stage I IDC patients, the patients in the intermediate- and high-risk classes showed a significantly higher tumor recurrence rate than the patients in the low-risk class (Table 2). Among the UICC pTNM stage II IDC

Table 1 Overall Allred score classification of p53 in tumor-stromal fibroblasts forming and not forming a fibrotic focus

<i>Invasive ductal carcinoma with a fibrotic focus</i>	
A) The Allred scores of p53 in tumor-stromal fibroblasts forming a fibrotic focus	Score class
0, 2, or 3	0
4-8	2
B) The Allred scores of p53 in tumor-stromal fibroblasts not forming a fibrotic focus	Score class
0 or 2	0
3	1
4-8	2
Total (A+B)	0-4
<i>Invasive ductal carcinoma without a fibrotic focus</i>	
The Allred scores of p53 in tumor-stromal fibroblasts not forming a fibrotic focus	Score class
0 or 2	0
3	1
4-8	2
Total	0-2
The Allred score risk classes for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci	
Low-risk class	0 and 1
Intermediate-risk class	2 and 3
High-risk class	4

Table 2 Tumor recurrence and tumor-related death rates according to the Allred score risk classes for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci in patients with invasive ductal carcinoma with or without a fibrotic focus

Risk classes	Cases	TRR (%)	P-value	MR (%)	P-value
<i>Invasive ductal carcinoma patients as a whole</i>					
Low-risk	648	36 (6)		9 (1)	
Intermediate-risk	232	52 (22)	<0.001	24 (10)	<0.001
High-risk	46	24 (52)	<0.001	15 (33)	0.001
Total	926	112 (12)		48 (5)	
<i>UICC pTNM stage I invasive ductal carcinoma patients</i>					
Low-risk	239	5 (2)		0	
Intermediate-risk	69	10 (15)	<0.001	4 (6)	<0.001
High-risk	6	2 (33)	0.295	0	0.454
Total	314	17 (5)		4 (1)	
<i>UICC pTNM stage II invasive ductal carcinoma patients</i>					
Low-risk	309	18 (6)		5 (2)	
Intermediate-risk	120	23 (19)	<0.001	7 (6)	0.045
High-risk	24	11 (46)	0.041	6 (25)	0.012
Total	453	52 (12)		18 (4)	
<i>UICC pTNM stage III invasive ductal carcinoma patients</i>					
Low-risk	100	13 (13)		4 (4)	
Intermediate-risk	43	19 (44)	<0.001	13 (30)	<0.001
High-risk	16	11 (69)	0.054	9 (56)	0.042
Total	159	43 (27)		26 (16)	

TRR, tumor recurrence rate; MR, mortality rate.




Figure 4 (a) Associations between the Allred scores for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci; the scores were significantly associated with each other ($P < 0.001$). (b) Associations between the Allred scores for p53 in tumor-stromal fibroblasts forming fibrotic foci and the diameter of the fibrotic foci. Invasive ductal carcinomas with fibrotic foci > 8 mm in diameter had a significantly higher Allred score for p53 in tumor-stromal fibroblasts forming fibrotic foci than those with fibrotic foci ≤ 8 mm in diameter ($P = 0.006$).

Figure 3 Tumor-stromal fibroblasts forming (a, c, e) and not forming a fibrotic focus (b, d, f). A fibrotic focus consists of tumor-stromal fibroblasts and hyalinized collagen fibers (a and c) and many tumor-stromal fibroblasts show a moderately intense nuclear staining pattern for p53. The Allred score for p53 in these tumor-stromal fibroblasts forming a fibrotic focus is 7 (intensity score, 2; proportion score, 5) (e). Carcinoma cells invade in irregular-shaped nests with a tubular structure (b) and tumor-stromal fibroblasts with oval nuclei not forming a fibrotic focus are seen (d). Many tumor-stromal fibroblasts not forming a fibrotic focus show a faint, moderate or strong intense nuclear staining pattern for p53, whereas tumor cells showing a faint intense nuclear staining pattern for p53 are visible (f). The Allred score for p53 in these tumor-stromal fibroblasts not forming a fibrotic focus is 8 (intensity score, 3; proportion score, 5).




Figure 5 Disease-free survival curves and overall survival curves of invasive ductal carcinoma (IDC) patients overall (a and b) according to the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming a fibrotic focus (FF). The disease-free survival time (a) and the overall survival time (b) of the IDC patients significantly decrease with the risk class of the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming FF.

patients, the tumor recurrence rate and the mortality rate for each risk class were significantly increased according to the risk classes of the classification (Table 2). Among the UICC pTNM stage III IDC patients, the patients in the intermediate-risk class showed a significantly higher tumor recurrence rate and mortality rate than the patients in the low-risk class, and the patients in the high-risk class showed a marginally significantly higher tumor recurrence rate and a significantly higher mortality rate than the patients in the intermediate-risk class (Table 2).

Overall, the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci (trend hazard rate, 2.9; trend 95% confidence interval, 1.6–5.2; *P*-value, <0.001) was superior to the Allred scores for p53 in tumor-stromal fibroblasts not forming fibrotic foci alone (trend hazard rate, 1.5; trend 95% confidence inter-

val, 0.8–2.6; *P*-value, 0.172) for accurately predicting tumor-related death among patients with IDC, as shown in a multivariate analysis.

Factors Significantly Associated with Tumor Recurrence and Tumor-Related Death

Among the patients with UICC pTNM stage I IDC, an intermediate-risk class (hazard rate, 6.2; 95% confidence interval, 2.1–18.5; *P*-value, 0.001) and a high-risk class (hazard rate, 11.6; 95% confidence interval, 2.1–63.8; *P*-value, 0.005) for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci and a histological grade of 3 (hazard rate, 2.9; 95% confidence interval, 1.1–7.6; *P*-value, 0.034) significantly increased the hazard rates for tumor recurrence in a multivariate analysis.

Among the patients with UICC pTNM stage II IDC, an intermediate-risk class and a high-risk class for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci significantly increased the hazard rates for tumor recurrence and tumor-related death in the multivariate analyses (Table 3). Grades 2 and 3 lymph vessel tumor emboli and the presence of blood vessel invasion significantly increased the hazard rates for tumor recurrence in the multivariate analysis (Table 3). A UICC pN1 category and a fibrotic focus diameter >8mm significantly increased the hazard rates for tumor-related death and an Allred score of 7 or 8 for the progesterone receptors in the tumor cells significantly decreased the hazard rate for tumor-related death in the multivariate analyses (Table 3).

Among the patients with a UICC pTNM stage III IDC, an intermediate-risk class and a high-risk class for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci, grade 3 lymph vessel tumor emboli and a UICC pN3 category significantly increased the hazard rates for tumor recurrence and tumor-related death in the multivariate analysis (Table 4). A fibrotic focus diameter >8mm significantly increased the hazard rate for tumor recurrence and an Allred score of 7 or 8 for estrogen receptor in the tumor cells significantly decreased the hazard rate for tumor-related death in the multivariate analysis (Table 4).

Discussion

This study clearly showed that the values of the Allred scores for p53 in tumor-stromal fibroblasts not forming fibrotic foci were significantly higher than those in tumor-stromal fibroblasts forming fibrotic foci. Fibrotic foci are fibrotic scar-like lesions that mainly consist of tumor-stromal fibroblasts admixed with various numbers of tumor cells; some fibrotic foci do not contain any tumor cells.^{1,2} In contrast, tumor-stromal fibroblasts not forming fibrotic foci commonly admix with many tumor cells that show stromal invasion. This difference

Table 3 Multivariate analyses for tumor recurrence and tumor-related death in UICC pTNM stage II invasive ductal carcinoma patients (n = 453)

Factors	Tumor recurrence		Tumor-related death	
	HR (95% CI)	P-value	HR (95% CI)	P-value
<i>p53 Allred score risk classes of tumor-stromal fibroblasts forming and not forming a fibrotic focus</i>				
Low-risk	Referent		Referent	
Intermediate-risk	3.5 (1.4–4.4)	0.003	3.3 (1.0–10.5)	0.043
High-risk	5.2 (1.8–6.5)	<0.001	4.7 (1.3–17.3)	0.021
<i>Grading system for lymph vessel tumor emboli</i>				
Grade 0	Referent		Referent	
Grade 1	1.5 (0.8–3.0)	0.226	0.5 (0.1–2.5)	0.421
Grades 2 and 3	2.5 (1.4–4.4)	0.003	2.0 (0.6–6.3)	0.275
<i>Blood vessel invasion</i>				
Absent	Referent		Referent	
Present	2.1 (1.1–3.8)	0.017	1.1 (0.3–3.8)	0.914
<i>The Allred scores for progesterone receptors in tumor cells</i>				
0 or 2	Referent		Referent	
3–6	—		0.8 (0.2–3.0)	0.729
7 or 8	—		0.2 (0.07–0.7)	0.009
<i>UICC pN category</i>				
pN0	Referent		Referent	
pN1	—		14.7 (1.9–113.1)	0.010
<i>Fibrotic focus, diameter</i>				
Absent	Referent		Referent	
≤ 8 mm	—		1.3 (0.2–8.5)	0.763
> 8 mm	—		3.4 (1.2–9.8)	0.025

HR, hazard rate; CI, confidence interval; —, not significance in univariate analysis.

The multivariate analysis for tumor recurrence was performed using the p53 Allred score risk classes in tumor-stromal fibroblasts forming and not forming a fibrotic focus, grading system for lymph vessel tumor emboli, blood vessel invasion, histological grade, and age.

The multivariate analysis for tumor-related death was performed using the p53 Allred score risk classes in tumor-stromal fibroblasts forming and not forming a fibrotic focus, grading system for lymph vessel tumor emboli, blood vessel invasion, the Allred scores for progesterone receptors in tumor cells, UICC pN category, fibrotic focus diameter, and age.

strongly suggests that the tumor cell–stromal cell interaction occurs more frequently in the outer area of a fibrotic focus than in the inner area of a fibrotic focus within IDCs,^{10,11} probably resulting in the higher Allred scores for p53 in tumor-stromal fibroblasts not forming fibrotic foci. However, the Allred scores for p53 in tumor-stromal fibroblasts forming fibrotic foci were significantly associated with those for p53 in tumor-stromal fibroblasts not forming fibrotic foci. Thus, the tumor cell–stromal cell interaction probably occurs more frequently in IDCs with fibrotic foci than in IDCs without fibrotic foci.

We and others have already reported that the fibrotic focus diameter is a significant outcome predictor among patients with IDC who have fibrotic foci,^{1–5} and our previous study showed that a fibrotic focus diameter of greater than 8 mm, similar to the Allred score for p53 in tumor-stromal fibroblasts not forming a fibrotic focus, was a significant outcome predictor for patients with IDC independent of the UICC pTNM stage.¹⁹ In this study, a fibrotic focus diameter was also a significant outcome predictor for IDC patients of UICC pTNM stage II and IDC patients of UICC pTNM stage III, and IDCs with fibrotic foci greater than 8 mm in diameter showed a significantly

higher Allred score for p53 in tumor-stromal fibroblasts forming fibrotic foci than IDCs with fibrotic foci of 8 mm or less in diameter. Thus, one can conclude that p53-expressing tumor-stromal fibroblasts located in both the inner and outer regions of fibrotic foci heighten the malignant potential of IDCs, probably accounting for the prognostic value of the fibrotic focus diameter. In addition, the grading system for lymph vessel tumor emboli significantly increased the hazard rates for tumor recurrence or tumor-related death in multivariate analyses performed for IDC patients with UICC pTNM stage II and UICC stage III. Therefore, the fibrotic focus diameter and the grading system for lymph vessel tumor emboli are likely to be very important histological outcome predictors for patients with IDC.

The results of this study clearly show that the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci had a greater outcome predictive power than the Allred scores for p53 in tumor-stromal fibroblasts not forming fibrotic foci alone. Furthermore, the Allred score risk classification for p53 in tumor-stromal fibroblasts forming and not forming fibrotic foci is a very important outcome predictor for patients with IDC